Literature DB >> 9359110

Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform.

D Neri1, B Carnemolla, A Nissim, A Leprini, G Querzè, E Balza, A Pini, L Tarli, C Halin, P Neri, L Zardi, G Winter.   

Abstract

The oncofetal fibronectin (B-FN) isoform is present in vessels of neoplastic tissues during angiogenesis but not in mature vessels. B-FN could therefore provide a target for diagnostic imaging and therapy of cancer. Phage display libraries have been used to isolate human antibody fragments with pan-species recognition of this isoform. We describe the use of these fragments in nude mice to target an aggressive tumor (grafted F9 murine teratocarcinoma). Imaging in real time was done by infrared photodetection of a chemically coupled fluorophore. The targeting was improved by use of affinity-matured fragments with low kinetic dissociation rates (koff = 1.5 x 10(-4) s-1) and also by engineering dimeric fragments via a C-terminal amphipathic helix.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359110     DOI: 10.1038/nbt1197-1271

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  50 in total

1.  Cellular activation of the self-quenched fluorescent reporter probe in tumor microenvironment.

Authors:  Alexei A Bogdanov; Charles P Lin; Maria Simonova; Lars Matuszewski; Ralph Weissleder
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

2.  Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases.

Authors:  M Yang; E Baranov; P Jiang; F X Sun; X M Li; L Li; S Hasegawa; M Bouvet; M Al-Tuwaijri; T Chishima; H Shimada; A R Moossa; S Penman; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 3.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

4.  A time domain fluorescence tomography system for small animal imaging.

Authors:  Anand T N Kumar; Scott B Raymond; Andrew K Dunn; Brian J Bacskai; David A Boas
Journal:  IEEE Trans Med Imaging       Date:  2008-08       Impact factor: 10.048

5.  Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Authors:  Patrizia Castellani; Laura Borsi; Barbara Carnemolla; Attila Birò; Alessandra Dorcaratto; Giuseppe L Viale; Dario Neri; Luciano Zardi
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

6.  Evaluation of CLT1-(Gd-DTPA) for Cancer MR Molecular Imaging in a Mouse Breast Cancer Model.

Authors:  Furong Ye; Eun-Kee Jeong; Denis Parker; Zheng-Rong Lu
Journal:  Bo Pu Xue Za Zhi       Date:  2011

7.  Targeting Fibronectin for Cancer Imaging and Therapy.

Authors:  Zheng Han; Zheng-Rong Lu
Journal:  J Mater Chem B       Date:  2016-12-01       Impact factor: 6.331

8.  Selection of phage-displayed peptides on live adherent cells in microfluidic channels.

Authors:  Jinpeng Wang; Yanli Liu; Tambet Teesalu; Kazuki N Sugahara; Venkata Ramana Kotamrajua; Jonathan D Adams; Brian S Ferguson; Qiang Gong; Seung Soo Oh; Andrew T Csordas; Minseon Cho; Erkki Ruoslahti; Yi Xiao; H Tom Soh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-12       Impact factor: 11.205

9.  Increased expression of fibronectin and the alpha 5 beta 1 integrin in angiogenic cerebral blood vessels of mice subject to hypobaric hypoxia.

Authors:  Richard Milner; Stephanie Hung; Bernadette Erokwu; Paula Dore-Duffy; Joseph C LaManna; Gregory J del Zoppo
Journal:  Mol Cell Neurosci       Date:  2008-02-13       Impact factor: 4.314

10.  Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Authors:  Kathrin Schwager; Manuela Kaspar; Frank Bootz; Roberto Marcolongo; Erberto Paresce; Dario Neri; Eveline Trachsel
Journal:  Arthritis Res Ther       Date:  2009-09-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.